Hinge Bio is advancing a novel therapeutic approach through its proprietary GEM-DIMER™ platform, which enables the development of multivalent and multispecific antibody-based therapeutics. This technology allows for cooperative binding to disease targets, significantly enhancing biological activity and providing unique functionalities that surpass traditional antibody therapies. The GEM-DIMER platform is designed to address challenges such as inadequate efficacy and resistance in various diseases, including cancer, autoimmune disorders, and infectious diseases. By creating molecules that can engage multiple targets simultaneously, Hinge Bio aims to improve treatment outcomes and safety profiles for patients.

The GEM-DIMER technology was developed by Hinge Bio's Chief Scientific Officer, Daniel Capon, Ph.D., who has a notable history of innovation in the field, including contributions to the development of recombinant Factor VIII and Fc-fusion proteins. The platform's versatility and ease of manufacture position it well for strategic partnerships with leading biopharmaceutical companies, facilitating the translation of these advanced therapeutics into clinical applications. Hinge Bio is currently focusing its efforts on oncology and autoimmune diseases, with ongoing preclinical studies to demonstrate the efficacy of its lead candidates.

United States

Hinge Bio, Inc. is a privately-held biotechnology company leveraging its powerful GEM-⁠DIMER™ platform to develop therapeutics that address the problems of resistance, inadequate efficacy, and side effects in the fields of cancer, inflammatory disease and infectious disease.

The GEM-DIMER™ technology uniquely enables (i) cooperative binding to disease targets allowing for orders-of-magnitude enhanced activity and (ii) greater degrees of multivalency and multispecificity than possible with conventional approaches, to produce molecules with entirely new functionality for superior safety and efficacy.

Hinge Bio

Company Details